When Gary Glick, Ph.D. left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.” Scorpion Therapeutics was born. Read more.
The post Scorpion Therapeutics debuts with $108M to ‘put the sting in cancer’ appeared first on Atlas Venture.